Search

Displaying results 2921 - 2930 of 7706 in total
  1. Drug

    Tribulus terrestris

    go.drugbank.com/drugs/DB14358
    Investigational

    It is not an approved drug.

    Mixtures: Medi DP Energy Bar
  2. Target

    Immunoglobulin kappa variable 2D-28

    go.drugbank.com/bio_entities/BE0004341
    TargetHumans

    V region of the variable domain of immunoglobulin light chains that participates in the antigen recognition (PubMed:24600447). Immunoglobulins, also known as antibodies, are membrane-bound or secreted glycoproteins produced by B lymphocy...

    Synonyms: Ig kappa chain V-II region FR
  3. Drug

    Magnesium gluconate

    go.drugbank.com/drugs/DB13749
    ApprovedWithdrawn

    Magnesium is ubiquitous in the human body, and is naturally present in many foods, added to other food products, available as a dietary supplement and used as an ingredient in some medicines (such as antacids

    Synonyms: Magnesium D-gluconate (1:2) hydrate, Magnesium D-gluconate (1:2) dihydrate
  4. Drug

    Sapropterin

    go.drugbank.com/drugs/DB00360
    ApprovedInvestigational

    Sapropterin (tetrahydrobiopterin or BH4) is a cofactor in the synthesis of nitric oxide. It is also essential in the conversion of phenylalanine to tyrosine by the enzyme phenylalanine-4-hydroxylase; the conversion of tyrosine to L-dopa ...

  5. Drug

    Flosequinan

    go.drugbank.com/drugs/DB13228
    ApprovedWithdrawn

    Flosequinan was approved in the USA and the UK for a year prior to being withdrawn from the market due to increased mortality in chronic heart failure patients, found in drug trials.[A174979,L43942]

  6. Drug

    Pegzilarginase

    go.drugbank.com/drugs/DB14780
    Approved

    FDA in February 2026 for the treatment of hyperargininemia in adult and pediatric patients aged 2 years and older with ARG1-D, to be used in conjunction with dietary protein restriction. … Pegzilarginase is a recombinant, cobalt-substituted, and pegylated human arginase 1 enzyme therapy designed to address the underlying metabolic deficit in arginase 1 deficiency (ARG1-D).

  7. Drug

    Anthrax immune globulin human

    go.drugbank.com/drugs/DB09057
    ApprovedInvestigational

    Available as the product Anthrasil (FDA), the result is a solution for slow IV infusion containing polyclonal antibodies that bind the protective antigen (PA) component of Bacillus anthracis lethal and

  8. Drug

    Ubrogepant

    go.drugbank.com/drugs/DB15328
    ApprovedInvestigational

    [L10926] It was approved by the FDA on December 23, 2019, and is the first oral calcitonin gene-related peptide (CGRP) receptor antagonist approved for the acute treatment of migraine. … [A189195] They appear to be better tolerated, do not contribute to medication overuse headaches, and carry no apparent cardiovascular risk, making them suitable for use in patients with cardiovascular

  9. Drug

    Epoetin delta

    go.drugbank.com/drugs/DB11624
    ApprovedWithdrawn

    Epoetin Delta is an ingredient in the EMA-withdrawn product Dynepo.

  10. Drug

    Parnaparin

    go.drugbank.com/drugs/DB09260
    Approved

    Parnaparin is an heparin of low molecular weight with antithrombotic effects.

    Products: FLUXUM 0.3 ML 3200 IU 2 HAZIR SIRINGA, FLUXUM 0.3 ML 3200 IU 6 HAZIR SIRINGA